Phibro Animal Health Corporation (PAHC)
- Previous Close
23.70 - Open
23.53 - Bid 16.72 x 200
- Ask 29.81 x 200
- Day's Range
23.12 - 23.68 - 52 Week Range
9.40 - 25.11 - Volume
93,858 - Avg. Volume
182,606 - Market Cap (intraday)
959.51M - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
385.33 - EPS (TTM)
0.06 - Earnings Date Nov 6, 2024
- Forward Dividend & Yield 0.48 (2.07%)
- Ex-Dividend Date Sep 4, 2024
- 1y Target Est
16.80
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
www.pahc.com1,940
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: PAHC
View MorePerformance Overview: PAHC
Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PAHC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PAHC
View MoreValuation Measures
Market Cap
937.25M
Enterprise Value
1.35B
Trailing P/E
385.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.92
Price/Book (mrq)
3.65
Enterprise Value/Revenue
1.32
Enterprise Value/EBITDA
19.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.24%
Return on Assets (ttm)
3.80%
Return on Equity (ttm)
0.90%
Revenue (ttm)
1.02B
Net Income Avi to Common (ttm)
2.42M
Diluted EPS (ttm)
0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
127.76M
Total Debt/Equity (mrq)
206.77%
Levered Free Cash Flow (ttm)
55.17M
Research Analysis: PAHC
View MoreCompany Insights: PAHC
PAHC does not have Company Insights
Research Reports: PAHC
View MoreLowering target price to $26.00
PHIBRO ANIMAL HEALTH CORP-A has an Investment Rating of BUY; a target price of $26.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about PAHC?
PHIBRO ANIMAL HEALTH CORP-A has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetRaising target price to $27.00
PHIBRO ANIMAL HEALTH CORP-A has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about PAHC?
PHIBRO ANIMAL HEALTH CORP-A has an Investment Rating of BUY; a target price of $24.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of High.
RatingPrice Target